Drug Profile
Epaminurad - JW Pharmaceutical
Alternative Names: SIM-0295; SIM-1909-13; URC-102Latest Information Update: 24 Apr 2023
Price :
$50
*
At a glance
- Originator JW Pharmaceutical
- Class Antigouts; Small molecules
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gout
- Phase I Kidney disorders
Most Recent Events
- 14 Mar 2023 Phase-III clinical trials in Gout (In adults, In the elderly) in South Korea (PO) (NCT05815901)
- 13 Jul 2022 JW Pharmaceutical completes a phase-I clinical trial in Kidney disorders (In volunteers) in South Korea (PO) (NCT05198778)
- 29 Nov 2021 Phase-I clinical trials in Kidney disorders (In volunteers) in South Korea (PO) (NCT05198778)